Metastatic HER2-positive breast cancerTrastuzumabPertuzumabTrastuzumab deruxtecanTucatinibTrastuzumab emtansineMargetuximabNeratinibDERUXTECAN T-DXDOPEN-LABELApproximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2+), conferring a particularly aggressive subtype of the disease...
Fig. 1. Sources of heterogeneity in HER2-positive breast cancer. Change of tumor phenotype from primary to metastasis Since in clinical practice we base our decisions on HER2 and HR status, it is important to highlight that tumor phenotype may change from primary tumor to metastasis. A recent...
Despite significantadvances in the treatmentofbreast cancer, approximately30%of patients go on to develop metastatic disease and recurrence. Further, nearly20%of breast cancers arehuman epidermal growth factor receptor 2 (HER)-positive.Managementof HER2-positive metastatic and advanced disease requires car...
Sara A. Hurvitz, MD, comments on her preferences for treating patients with HER2-positive metastatic breast cancer and shares her strategy for sequencing therapies.
metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. About MARGENZA MARGENZA is an infusion that was approved by the US Food and Drug Administration (FDA) in 2020. ...
Conclusion: It could be shown that, compared to historical controls, targeted therapy against HER2 prolongs overall survival of patients with HER2-positive metastatic breast cancer who receive treatment in routine care.doi:10.5539/cco.v2n1p17Rudolf Weide...
HER2-positive (HER2+) metastatic breast cancer (mBC) is highly aggressive and a major threat to human health. Despite the significant improvement in patients’ prognosis given the drug development efforts during the past several decades, many clinical questions still remain to be addressed such as ...
Surya K. De, in Medicines for Cancer, 2023 6.5.1 Indications (medical uses) Metastatic breast cancer (a) It is used in adult patients with unresectable or metastatic HER2-positive breast cancer who have received at least two anti-HER2-based regimens in the metastatic setting. Locally ...
The present review summarizes the currently available data on targeted anti-her2 therapies from completed randomized phase iii clinical trials and briefly discusses emerging advances that will address unmet needs in metastatic her2-positive breast cancer. 展开 关键词: her2 metastatic breast cancer phase ...
the expression and amplification of the human epidermal growth factor receptor type 2 (HER2), breast cancer can be divided into three clinical subtypes: hormone-receptor (HR)-positive (HR+; ER+, PR+/– and HER2–), HER2-positive (HER2+) and triple-negative (TN; ER–, PR– and HER2–...